High frequency oscillatory ventilation has been shown to improve oxygenation of patients with severe respiratory failure. This prospective study examined the potential benefits and risks of the latest generation high frequency oscillatory ventilator (R100, Metran, Saitama, Japan), initiated when the target oxygenation could not be achieved by conventional mechanical ventilation in adult patients with severe hypoxaemic respiratory failure. Thirty-six patients with severe respiratory failure treated with the R100 high frequency oscillatory ventilator were considered. Pneumonia and exacerbation of interstitial pneumonia were the main causes of respiratory failure. The median time on conventional mechanical ventilation or airway pressure release ventilation prior to high frequency oscillatory ventilation was 9.3 hours (interquartile range 4.8 to 25). P a O 2 /FiO 2 at 24 hours after initiation of high frequency oscillatory ventilation was significantly better than the P a O 2 /FiO 2 at baseline (151.2±61.2 vs 99.5±50.0, P=0.0001). Refractory hypoxaemia within 24 hours was associated with a high risk of mortality (P=0.0092) and 23 patients (64%), including 11 patients with exacerbation of interstitial pneumonia, died by 30 days. Of the 36 patients included in the study (including one who had developed pneumothorax before high frequency oscillatory ventilation), 12 (33%) developed barotrauma during the course of their intensive care unit stay. In the multivariate analysis, only exacerbation of interstitial pneumonia was a significant risk factor for barotrauma. In summary, the latest generation high frequency oscillatory ventilator could improve oxygenation in adult patients with life-threatening hypoxaemic respiratory failure but the incidence of barotrauma was substantial.
Mechanical ventilation may induce ventilatorassociated lung injury and multi-organ failure by repetitive opening and closure and over-distention of alveoli in patients with severe hypoxaemic respiratory failure 1 . Low tidal volume ventilation, permissive hypercapnia and high positive end-expiratory pressure have been suggested as ways to reduce ventilatorassociated lung injury during mechanical ventilation 2 .
High frequency oscillatory ventilation (HFOV) is characterised by high mean airway pressure (MAP) to prevent atelectasis and extremely small tidal volumes. Theoretically, HFOV is an ideal ventilatory mode for lung protection 3 . There are some reports on the effectiveness of the 3100B HFOV ventilator (SensorMedics, Yorba Linda, California, USA) which is commonly used in the United States of America and Europe; however, whether HFOV can improve mortality of patients with severe hypoxaemic respiratory failure remains unproven.
The R100 HFOV ventilator (Metran, Saitama, Japan) has been used in patients with severe hypoxaemic respiratory failure, such as acute lung injury/acute respiratory distress syndrome, in Japan since 2004. We examined the benefits and risks associated with the use of R100 HFOV for patients with severe hypoxaemic respiratory failure who did not respond to conventional controlled mechanical ventilation (CMV).
MATERIALS AND METHODS
This prospective observational study was approved by the Ethical Committee of Tosei General Hospital (ethics approval number was not issued by this committee). Informed consent was obtained from the patients' next of kin prior to study entry.
Patients were enrolled if they met the following criteria: SpO 2 <88% or P a O 2 <60 mmHg on FiO 2 >0.6 in oxygenation or pH <7.20 in respiratory acidosis after several hours of applying CMV with high positive end-expiratory pressure (>15 cmH 2 O) and low tidal volumes (6 to 8 ml/kg ideal body weight). Patients were excluded if they had severe chronic obstructive pulmonary disease or bronchial asthma, severe shock (i.e. despite adequate fluid resuscitation requiring vasopressor support of at least 0.25 μg/kg/minute of noradrenaline) and severe air leak from the respiratory system (i.e. more than one chest tube required per hemithorax with a persistent air leak of more than 120 hours).
We used the Metran R100, which was introduced into clinical use from 2004 in Japan, as a HFOV ventilator for adult patients. The R100 HFOV ventilator has dimensions of about 1600×770× 550 mm and a weight of about 80 kg. Therefore it is larger than the older version 3100B HFOV. The oscillation of R100 is provided from a diaphragm on the anterior side of the ventilator which is driven by a rotary valve mechanism ( Figure 1 ). The available settings include MAP with a range of 5 to 65 cmH 2 O, frequency of 5 to 15 Hz, sigh pressure of 5 to 80 cmH 2 O and stroke volume (SV) of 100 to 350 ml. The I:E ratio of the respiratory cycle is fixed at 1:1, whereas the I:E ratio of the SensorMedics 3100B can be changed. Amplitude (ΔP; cmH 2 O) is automatically measured and manually controlled by the SV while the ventilator is working. Additionally, the R100 has conventional ventilatory modes such as synchronised intermittent mandatory ventilation with volume or pressure control, pressure support ventilation and continuous positive airway pressure mode. Conventional ventilation can be easily changed to HFOV with a single rotary switch.
HFOV strategy
HFOV was started with FiO 2 1.0 and MAP at 5 cmH 2 O higher than MAP on CMV. SpO 2 was targeted to 88 to 95% as an indicator of oxygenation. MAP was increased appropriately until the target oxygenation was achieved; however, maximum MAP was limited to about 30 to 35 cmH 2 O by the protocol. This was because the haemodynamic status of the patients was often affected even when volume resuscitation was adequate. Recruitment manoeuvres were done with 40 cmH 2 O over 30 to 40 seconds only when they were necessary in initiating HFOV, but not routinely 4 . Recruitment manoeuvres were applied if increasing MAP did not result in target oxygen saturation and there seemed to be recruitable lesions such as consolidation in the lung, which were checked by chest X-rays or computed tomography. Nitric oxide, prone positioning, prostacyclin nebulisation and extracorporeal membrane oxygenation were not applied in our patients. When SpO 2 reached the target value and became stable, FiO 2 was gradually reduced to 0.6 by 0.05 decrements every 15 to 30 minutes and then MAP was reduced to 18 to 22 cmH 2 O by 2 cmH 2 O decrements every six to 12 hours 5 . We applied a permissive hypercapnia strategy in which the target P a CO 2 was between 40 to 70 mmHg, providing that the pH was >7.2 5 . SV, which was related to the amplitude of oscillation, was initially started with 120 to 150 ml. (This was adjusted as dead space in the adult lung.) SV gradually increased until chest wall vibration was visible to the level of the mid-thigh, however, amplitude was targeted to <90 cmH 2 O 5 . In addition, frequency was set as high as possible, but limited to 10 Hz. SV and frequency were sequentially adjusted according to P a CO 2 and pH within the target range. Patients were deeply sedated with propofol and opioids, targeting minus 3 on the Richmond Agitation Sedation Scale (RASS) 6 . Continuous infusion of neuromuscular blocking agents was never used for HFOV. Patients were switched from HFOV back to CMV when FiO 2 was less than 0.5, and MAP was weaned to 18 to 22 cmH 2 O or less with target oxygenation. If adverse events such as barotrauma occurred in the patient, we decided in conference whether HFOV could be continued or not, considering the general condition of the patient.
Outcome measurements
The objective of this study was to describe physiological and outcome parameters in patients managed with the R100 for refractory hypoxaemia during CMV.
We investigated hospital mortality, mortality at 30 days, survival rate without mechanical ventilation and oxygen at 30 days and trends in oxygenation. We also studied adverse events such as hypotension and barotrauma related to HFOV settings. We recorded patient data including the period of CMV prior to HFOV, Acute Physiology and Chronic Health Evaluation (APACHE) II score at admission, Sequential Organ Failure Assessment (SOFA) score at admission, arterial blood gases, ventilator settings and haemodynamic parameters. Arterial blood gases were recorded at the start of HFOV treatment, two hours after the start of HFOV treatment and every 24 hours for the first three days.
Data analysis
Data are given as mean and standard deviation. We used the χ 2 test or Fisher Exact test (as appropriate) to compare categorical variables between the two study groups and the Wilcoxon-Mann-Whitney two-sample rank-sum test or t-tests to compare continuous variables. Subgroup analysis compared mortality at 30 days, APACHE II, gas exchange and ventilation time in the following subsets of patients: a) one group defined as a responsive group by a stable increase in the ΔP a O 2 /FiO 2 of over 50 and another group as a refractory group by a ΔP a O 2 / FiO 2 of less than 50 following 24 hours of HFOV treatment (or the last measurement if HFOV ended within the first 24 hours); b) a barotrauma group and no-barotrauma group. A cumulative event curve was estimated with the Kaplan-Meier procedure. Response to HFOV treatment was compared for differences in mortality by Kaplan-Meier survival analysis and the log-rank test. Parameters in the multivariate analysis of barotrauma included age, gender, APACHE II, the period of CMV prior to HFOV, P a O 2 /FiO 2 at start of CMV and HFOV, MAP and SV at start of HFOV, exacerbation of interstitial pneumonia and steroid use. P values were calculated as two-sided. P values less than 0.05 were considered statistically significant. Analyses were performed using SPSS version 17.0 for Windows software (SPSS Inc., Chicago, Illinois, USA).
RESULTS

Patient characteristics
Of the 53 patients who met the inclusion criteria, 36 patients were enrolled in the eight-bed intensive care unit from July 2004 to December 2009. Seventeen patients who were excluded from this study were ventilated with airway pressure release ventilation (APRV) after initial CMV. Of these, 11 patients had a good response to APRV and two patients had barotrauma. Of the six patients who did not respond to APRV, four patients could not undergo HFOV due to circulatory instability and two patients due to excessive barotrauma. Patient characteristics at study entry are summarised in Table 1 . The youngest patient was 15 years of age and the oldest patient was 86. APACHE II score at time of intensive care unit admission was 26.4 (SD=7.1; APACHE II predicted mortality: 58.4%). Pneumonia and exacerbation of interstitial pneumonia were the main causes of respiratory failure. Of 14 patients with interstitial pneumonia, six were diagnosed by lung biopsy and eight were diagnosed by the presence of a honeycomb pattern in high-resolution chest computed tomography as agreed by more than two respiratory physicians.
Six patients received APRV after CMV and then were switched to HFOV. The median time on CMV or APRV prior to HFOV was 9.3 hours (interquartile Mechanical ventilation settings R100 settings over the first 72 hours after the start of HFOV are summarised in Table 2 . Mean airway pressure decreased gradually after 48 hours, whereas amplitude, stroke volume and frequency remained at the initial values. Seven of 36 patients were taken off HFOV within 24 hours. Of these seven patients, three died, one developed hypotension, one suffered from barotrauma, one had worsened oxygenation and the last one was weaned from HFOV.
Arterial blood gas responses
The P a O 2 /FiO 2 showed progressive deterioration and was 99.5±50.0 just prior to HFOV. The oxygenation index also worsened from 16.4±8.8 at the start of CMV to 23.6±15.8 at the start of HFOV. Pulmonary oxygenation at baseline, two hours and 24 hours after the start of HFOV (or at the last point of measurement if HFOV ended within the first 24 hours) is shown in Figure 2 . The mean P a O 2 / FiO 2 increased significantly from the baseline level by 24 hours after the start of HFOV or at the last point of measurement (151.2±61.2 vs 99.5±50.0, P=0.0001). On the other hand, oxygenation index deteriorated at two hours and then gradually improved until 24 hours, although the difference was not significant (19.5±10.6 vs 23.6±15.8, P=0.22).
The P a CO 2 and pH responses are summarised in Table 3 . They were also investigated in the 36 patients with P a CO 2 <45 mmHg (normocapnic group, n=18) or P a CO 2 >45 mmHg (hypercapnic group, n=18) before HFOV, separately. In the hypercapnic group P a CO 2 decreased gradually, leading to almost normal pH level.
Haemodynamic responses
Haemodynamic parameters in patients ventilated with R100 are shown in Table 4 . Blood volume status was monitored by central venous catheter or Swan-Ganz catheter. Swan-Ganz catheters were inserted in 47% (17 of 36) of all patients. There were no remarkable changes in mean haemodynamic parameters during HFOV.
Outcomes
Thirty patients (83%), including cases of successful weaning and discontinuation due to adverse events, Data are presented as mean ± standard deviation. * Normocapnic group includes patients with P a CO 2 <45 mmHg before highfrequency oscillatory ventilation. † Hypercapnic group includes patients with P a CO 2 >45 mmHg before high-frequency oscillatory ventilation. were taken off HFOV and put on pressure control ventilation. A total of 23 patients (64%) died within 30 days ( Figure 3 ) and six died while they were still treated with HFOV. Seven patients died from refractory respiratory failure, 15 died from multiorgan failure and one died from circulatory failure. Only eight patients (22%) survived at 30 days without requiring mechanical ventilation and the overall hospital mortality of the entire cohort was 83% (30/36) ( Table 5 ). Hospital mortality for patients with exacerbation of interstitial pneumonia and those with respiratory failure from other causes were 100% and 73%, respectively.
Adverse events
A total of 12 patients (33%) developed barotrauma during HFOV, eight (22%) with pneumothorax, one (3%) with subcutaneous emphysema, two (6%) with subcutaneous emphysema and pneumomediastinum, and one (3%) with pneumothorax and pneumomediastinum. Of the 12 patients with barotrauma, one patient had developed a spontaneous pneumothorax one month before and one patient had undergone surgical lung biopsy seven days previously and then developed pneumothorax on the same side. The diagnosis in seven of the 12 patients in the barotrauma group was exacerbation of interstitial pneumonia. There were no significant differences between the barotrauma group and no-barotrauma group in the patient characteristics, ventilator settings or outcomes. Survival at hospital discharge was 8% in the barotrauma group and 21% in the nobarotrauma group (P=0.64). Barotrauma occurred at 48.2 hours after initiation of HFOV on average. When barotrauma occurred, the ventilator settings of the 12 patients were MAP 24.5±6.9 cmH 2 O, SV 154.6±34.1 ml, amplitude 69.7±27.0 cmH 2 O and frequency 8.6±1.2 Hz. Exacerbation of interstitial pneumonia was the only significant risk factor for barotrauma in the stepwise logistic regression analysis (odds ratio 6.86, 95% confidence interval 1.15 to 40.98; P=0.035). A total of nine patients developed haemodynamic adverse events during HFOV; seven patients (19%) developed significant hypotension, one patient (3%) had a cardiac arrest and one patient had (3%) severe tachycardia.
Outcome effect of oxygenation response to R100
The time course of the P a O 2 /FiO 2 for the 36 patients was analysed for the first 24 hours of HFOV. In 19 patients (responsive group) there was a marked increase in P a O 2 /FiO 2 of over 50 at 24 hours after the start of HFOV compared to the baseline (change in P a O 2 /FiO 2 91.2±37.5 mmHg) 7 . Seventeen patients (refractory group) failed to meet the P a O 2 /FiO 2 target despite HFOV (change in P a O 2 /FiO 2 7.7±27.7 mmHg). After 30 days, nine of the responsive group (47%) and 14 of the refractory group (82%) had died. The results of the log-rank test and the Kaplan-Meier curve are shown in Figure 4 (P=0.0092). Patient characteristics between the responsive and refractory groups were not significantly different ( Table 6 ). The mean duration of HFOV treatment was 4.4 days in the responsive group and 2.6 days in the refractory group.
DISCUSSION
Although there are several reports on outcomes of patients treated with HFOV using the 3100B from the USA and Europe, to our knowledge this is the first clinical study on benefits and risks of HFOV using the R100 on patients with refractory hypoxaemic respiratory failure.
The R100 can be regarded as a SV-regulated HFOV machine that is different from the older generation pressure-amplitude regulated 3100B. However, the R100 cannot control the delivered tidal volume in a uniform fashion. A benchtop study showed that the delivered tidal volume varies with compliance, endotracheal tube size and HFOV frequency; tidal volume increased as compliance increased, as endotracheal tube size increased and as frequency of oscillations decreased 8 . Although similar relationships between tidal volume and endotracheal tube size or frequency of oscillations with 3100B were also reported by Hager et al 9 , the relationship between tidal volume and compliance appeared to be different between the R100 and 3100B. The tidal volume delivered by the R100 appears to be more strongly influenced by respiratory compliance than the tidal volume delivered by the 3100B 8,9 . Lung-protective ventilation strategy has a twoarmed approach to avoid the exacerbation of lung injury during mechanical ventilation. One arm is to use small tidal volume (<6 to 8 ml/kg ideal body weight) to avoid over-distention of alveoli. The other arm is to keep the alveoli open with high positive end-expiratory pressure and avoid repetitive alveolar collapse and reopening 10, 11 . Using this lungprotective strategy during CMV, severe hypoxaemia and hypercapnia with respiratory acidosis may still occur in many patients with severe respiratory failure. Previous studies reported that HFOV might be more effective than CMV in improving oxygenation and ventilation for patients with refractory hypoxaemia and hypercapnia 7, [12] [13] [14] [15] and that HFOV suppressed inflammatory response in the lung by reducing the repetitive collapse and opening or over-distention of alveoli 16 .
In this study, the P a O 2 /FiO 2 showed a gradual improvement after a 24-hour period of R100 HFOV treatment, similar to results of 3100B HFOV 7, 12, 13, 15, 17, 18 . Compared to the improvement in P a O 2 /FiO 2 after the start of HFOV, the change in the oxygenation index (which has been regarded as a marker of lung injury and prognostic indicator of treatment success) was slow and became significant only after 72 hours ( Table 2 ). Although the delay of improvement in oxygenation index versus P a O 2 /FiO 2 was also similar to the results of using 3100B HFOV 13 , the response in oxygenation index was slower in our patients. This might be due to the fact that a large number of our patients had severe parenchymal lung damage and extremely low lung compliance. Despite the improvement in oxygenation, HFOV did not seem to reduce the mortality. The survival rate of our patients at 30 days was 36% and that without ventilatory support was only 22%. The mortality was a little higher than predicted mortality (58.4%) and much higher than those reported in previous studies. This may be related to the fact that a large proportion of our patients (39%) had severe interstitial pneumonia which is considered as one of the most lifethreatening respiratory conditions and its mortality effect may not be fully captured by the APACHE II prognostic model. Because the outcomes of interstitial pneumonia are so poor, some clinicians would not recommend initiating mechanical ventilation for these patients when they have very severe respiratory failure 19 .
Although HFOV may theoretically induce less lung injury than CMV, the incidence of barotrauma in this study was still substantially higher (31%) than those reported with 3100B HFOV (2.7% to 9%) 17, 18 . There are three possible explanations.
First, the main difference between the R100 and 3100B is in the delivery of a fixed stroke volume compared with a fixed pressure. Similarly to volume control ventilation in CMV, the airway pressure may be susceptible to the changes in lung compliance during ventilation with a R100 ventilator. In fact, amplitude at 24 hours was a little higher in our study (77.0±22.7 cmH 2 O) than in Derdak's report (66±14 cmH 2 O) 17 or Bollen's (63±14 cmH 2 O) 18 , while mean MAP at 24 hours was lower in our study (24.6±4.7 cmH 2 O versus 29±6 cmH 2 O, 30±5.6 cmH 2 O, respectively). It is thus possible that the actual peak airway pressure and tidal volume used in this study were higher than in previous reports.
Second, severe hypoxaemic respiratory failure in our patients was primarily due to pulmonary causes, with exacerbation of interstitial pneumonia or pulmonary infection accounting for 78% of the diagnoses. This is very different from the reports by Derdak and Bollen 17, 18 in which extra-pulmonary causes, such as sepsis and trauma, were the predominant causes of respiratory failure. In fact, we found exacerbation of interstitial pneumonia to be a marked risk for barotrauma in multivariate analysis (P=0.035).
Third, we targeted sedation level of patients during HFOV at minus 3 on the RASS and neuromuscular blocking agents were used rarely. Respiratory effort or cough of some of our patients might lead to intermittent high peak airway pressure, leading to increased risk of barotrauma.
This study has limitations. First, this observational study did not include patients who had similar severity of illness but who were not treated with R100 HFOV. As such, we cannot be certain whether this new HFOV is better than CMV or older generation HFOV. Second, the number of patients in this study was very small and underpowered to determine multiple predictive factors of mortality and barotrauma. Finally, 14 of 36 patients enrolled in this study had exacerbation of interstitial pneumonia and this might have led to higher mortality and morbidity of barotrauma than previous studies 7, 12, 13, 15, 17, 18 .
In summary, the R100 HFOV ventilator improved the oxygenation of patients with severe hypoxaemia when oxygenation could not be maintained by CMV. Although the R100 may be used as a rescue therapy for patients with life-threatening respiratory failure, the risk of barotrauma remains a major concern, especially for patients with exacerbation of interstitial pneumonia.
